Nature Medicine：抗LAG-3单抗治疗复发性胶质母细胞瘤临床数据发布

TL;DR - A Nature Medicine phase 1 trial found acceptable safety and preliminary clinical and immune signals for the anti-LAG-3 antibody relatlimab, alone or with nivolumab, in recurrent glioblastoma.

• The multicenter, open-label trial treated 46 patients, split equally between monotherapy and combination groups.
• Six combination-treated patients had grade 3–4 treatment-related adverse events; none occurred with monotherapy.
• Neoadjuvant treatment increased intratumoral CD8+ T-cell infiltration.
• Twelve-month overall survival was 34.8% with relatlimab and 52.2% with the combination, but the trial was not designed to assess efficacy.